Asthma is a long-term inflammatory airway condition that frequently coexists with cardiovascular disorders, making treatment difficult, especially when beta blockers are required. By blockingβ2-adrenergic receptors, beta blockers—especially non-selective ones—may worsen asthma by decreasing the effectiveness of bronchodilators. Conversely, asthma drugs, particularlyβ2-agonists, may mitigate the beneficial effects of beta blockers on the heart. This study covers the causes, dangers, and evidence-based co-management techniques regarding the pharmacological and clinical interactions between beta blockers and asthma medications. This article provides physicians with a roadmap for navigating the intricate junction of respiratory and cardiovascular pharmacology, emphasizing pharmacodynamics, pharmacokinetics, and customized treatment.